CoViD-19: Semperit supports Austrian government initiative – “Glove-liner“ bring more than 60 million protective gloves to Austria

In view of the current developments surrounding the Corona/CoVid-19 virus, the publicly listed Semperit Group, in cooperation with the crisis management team of the Austrian federal government, delivers more than 60 million gloves to provide protective equipment for medical personnel in Austria.

The examination and protective gloves, which are produced at the Sempermed production site in Kamunting, Malaysia, will be brought to Austria on four flights operated by Austrian Airlines until the end of April 2020; distribution will be handled by the Red Cross. The first "Glove-liner" lands tomorrow, Friday.

"We are pleased that we are able to contribute to a better management of the Corona crisis in Austria with our medical protective gloves and we are proud of our employees, who are making this possible even in this difficult situation with their tireless efforts close to their limits," says Dr. Martin Füllenbach, Chief Executive Officer of Semperit AG Holding.


Monika Riedel
Director Group Brand Management, Corporate Spokesperson
+43 676 8715 8620

Judit Helenyi
Director Investor Relations
+43 676 8715 8310

About Semperit:
The publicly listed company Semperit AG Holding is an internationally-oriented group that develops, produces, and sells in more than 100 countries highly specialised rubber products for the medical and industrial sectors: examination and surgical gloves, hydraulic and industrial hoses, conveyor belts, escalator handrails, construction profiles, cable car rings, and products for railway superstructures. The headquarters of this long-standing Austrian company, which was founded in 1824, are located in Vienna. The Semperit Group employs around 6,900 people worldwide, including about 3,600 in Asia and around 900 in Austria (Vienna and production site in Wimpassing, Lower Austria). The Group has 14 manufacturing facilities worldwide and numerous sales offices in Europe, Asia, Australia, and America. In 2018, the group generated revenue of EUR 840.6 million and an adjusted EBITDA (without one-off effects) of EUR 63.8 million.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)